Drug Trial Radar · NCT03845387
A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.
Last checked: Nov 20, 2026Latest source record: Feb 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
Feb 26, 2019
Primary completion
Feb 21, 2020
Study completion Feb 21, 2020
Sponsor
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objective of this study is to investigate the efficacy, safety and pharmacokinetics of KDT-3594 in patients with early Parkinson's disease without a concomitant medication of L-dopa.
Conditions
- Parkinson Disease
Interventions
KDT-3594Drug
oral administration, dose titration
PramipexoleDrug
ER formulation, oral administration, dose titration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scoreTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Multiple Locations, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.